Aclaris Therapeutics Management
Management criteria checks 4/4
Aclaris Therapeutics' CEO is Neal Walker, appointed in Jul 2012, has a tenure of 12.33 years. directly owns 1.93% of the company’s shares, worth $6.32M. The average tenure of the management team and the board of directors is 2.4 years and 10.5 years respectively.
Key information
Neal Walker
Chief executive officer
US$73.5k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 12.3yrs |
| CEO ownership | 1.9% |
| Management average tenure | 2.4yrs |
| Board average tenure | 10.5yrs |
Recent management updates
Recent updates
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 12
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?
Aug 08We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up
Mar 07Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report
Mar 01Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 19Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 11Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results
Aug 10What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today
Aug 08Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Jun 06We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions
Oct 06Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata
Aug 25Aclaris Therapeutics gets a new COO
Aug 01Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
May 28We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
Dec 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$37m |
| Jun 30 2024 | n/a | n/a | -US$59m |
| Mar 31 2024 | n/a | n/a | -US$77m |
| Dec 31 2023 | US$74k | n/a | -US$88m |
| Sep 30 2023 | n/a | n/a | -US$115m |
| Jun 30 2023 | n/a | n/a | -US$105m |
| Mar 31 2023 | n/a | n/a | -US$96m |
| Dec 31 2022 | US$6m | US$590k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | n/a | n/a | -US$83m |
| Mar 31 2022 | n/a | n/a | -US$81m |
| Dec 31 2021 | US$7m | US$567k | -US$91m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | n/a | n/a | -US$71m |
| Mar 31 2021 | n/a | n/a | -US$65m |
| Dec 31 2020 | US$2m | US$424k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$57m |
| Jun 30 2020 | n/a | n/a | -US$69m |
| Mar 31 2020 | n/a | n/a | -US$102m |
| Dec 31 2019 | US$3m | US$500k | -US$114m |
| Sep 30 2019 | n/a | n/a | -US$118m |
| Jun 30 2019 | n/a | n/a | -US$115m |
| Mar 31 2019 | n/a | n/a | -US$79m |
| Dec 31 2018 | US$4m | US$550k | -US$82m |
| Sep 30 2018 | n/a | n/a | -US$81m |
| Jun 30 2018 | n/a | n/a | -US$79m |
| Mar 31 2018 | n/a | n/a | -US$86m |
| Dec 31 2017 | US$810k | US$510k | -US$50m |
Compensation vs Market: Neal's total compensation ($USD73.50K) is below average for companies of similar size in the US market ($USD2.18M).
Compensation vs Earnings: Neal's compensation has been consistent with company performance over the past year.
CEO
Neal Walker (54 yo)
12.3yrs
Tenure
US$73,500
Compensation
Dr. Neal S. Walker, D.O. & M.D., is Venture Partner of Forge Life Science Partners. He Co-founded Aclaris Therapeutics, Inc. in 2012 and has been its Director since July 2012 and serves as its Chairman sin...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$73.50k | 1.93% $ 6.3m | |
| Chief Financial Officer | 1.8yrs | US$2.34m | 0.035% $ 113.3k | |
| Chief Scientific Officer | 3.8yrs | US$2.26m | 0.26% $ 858.2k | |
| Chief Business Officer | 2.8yrs | US$2.33m | 0.048% $ 156.1k | |
| General Counsel & Corporate Secretary | 2.4yrs | no data | no data | |
| Senior Vice President of Chemistry | no data | no data | no data | |
| Senior Vice President of Project Leadership | less than a year | no data | no data | |
| Senior Vice President of Clinical Development | less than a year | no data | no data |
2.4yrs
Average Tenure
56.5yo
Average Age
Experienced Management: ACRS's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$73.50k | 1.93% $ 6.3m | |
| Independent Director | 4.8yrs | US$180.38k | 0.018% $ 57.5k | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 10.2yrs | US$194.38k | 0.061% $ 199.0k | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Lead Independent Director | 10.8yrs | US$206.88k | 0.074% $ 244.0k | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data |
10.5yrs
Average Tenure
60yo
Average Age
Experienced Board: ACRS's board of directors are seasoned and experienced ( 10.5 years average tenure).